Every 8-K that Prime Medicine, Inc. (PRME) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PRME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRME filings page.
Prime Medicine, Inc. reported second quarter 2026 results and pipeline updates. Collaboration revenue was modest while operating expenses declined, with research and development at $33.4 million and general and administrative at $11.0 million. Net loss narrowed to $42.1 million and cash, cash equivalents, investments and restricted cash totaled $108.8 million as of June 30, 2026, which the company expects will fund operations into 2027.
Programmatically, IND and CTA clearances in the United States and New Zealand established a global Phase 1/2 program for PM577a in Wilson disease, with initial data expected in 2027. A favorable arbitration outcome with Beam Therapeutics confirmed Prime Medicine’s rights to PM647 in Alpha-1 Antitrypsin Deficiency, with an IND and/or CTA submission planned for the third quarter of 2026. The FDA granted Regenerative Medicine Advanced Therapy designation to PM359 in chronic granulomatous disease, and the company is engaging toward a potential BLA submission in the first half of 2027.
Prime Medicine, Inc. reported that an arbitration tribunal issued a final award resolving its dispute with Beam Therapeutics over their 2019 Collaboration and License Agreement. The tribunal declared that PM647, Prime Medicine’s development candidate for treating Alpha-1 Antitrypsin Deficiency, falls within Prime Medicine’s contractual field and that the company did not breach the agreement. As a result, the tribunal denied Beam’s requests for damages and injunctive relief based on its breach allegations. The tribunal also denied the remaining claims brought by both Beam and Prime Medicine.
Prime Medicine, Inc. held its 2026 annual stockholder meeting on June 5, 2026 via live webcast. A quorum was established with 140,384,724 shares present or represented by proxy out of 180,615,889 shares of common stock entitled to vote as of the April 9, 2026 record date.
Stockholders elected Michael Kelly and David Schenkein, M.D. as Class I directors to serve until the 2029 annual meeting, with 107,059,058 and 87,522,409 votes "for," respectively. They also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 139,989,201 votes in favor.
Prime Medicine, Inc. reported first quarter 2026 results showing continued investment in its gene-editing pipeline alongside a slightly narrower loss. Collaboration revenue was $0.9 million, while research and development expenses fell to $34.1 million from $40.6 million a year earlier as the company focused on its in vivo liver franchise.
General and administrative expenses increased to $17.4 million, largely due to arbitration-related legal costs. Net loss was $49.1 million, compared with $51.9 million in the prior-year quarter. As of March 31, 2026, cash, cash equivalents, investments and restricted cash totaled $149.2 million, which the company expects will fund operations into 2027.
Operationally, Prime Medicine highlighted progress toward regulatory filings for PM577 in Wilson Disease and PM647 in Alpha‑1 Antitrypsin Deficiency in 2026, continued regulatory dialogue on a potential BLA for PM359 in Chronic Granulomatous Disease, and the appointment of Svetlana Makhni as Chief Financial Officer.
Prime Medicine, Inc. has appointed Svetlana Makhni as Chief Financial Officer and principal financial officer, effective April 16, 2026. She brings over 20 years of biotechnology, healthcare and investment banking experience, including prior CFO roles at Marengo Therapeutics, Escient Pharmaceuticals and Bierman ABA.
Under her employment agreement, Ms. Makhni will receive a $495,000 annual base salary, a $40,000 sign-on bonus and is eligible for an annual bonus targeted at 40% of base salary. The package includes standard severance protections, enhanced if a qualifying termination occurs within 12 months of a change in control.
The Board also approved stock options for 800,000 time-vested shares and an additional 100,000 performance-vested shares under the 2022 Stock Option and Incentive Plan. Existing CEO Allan Reine, M.D. will step down as principal financial officer but will remain Chief Executive Officer and principal executive officer.
Prime Medicine, Inc. reported full-year 2025 results and detailed progress across its gene-editing pipeline. Total collaboration revenue was $4.6M, up from $3.0M in 2024, while research and development expenses rose to $160.6M and general and administrative expenses to $52.3M. Net loss widened slightly to $201.1M, or $1.35 per share, compared with a $195.9M loss, or $1.65 per share, a year earlier. Cash, cash equivalents, investments and restricted cash totaled $191.4M as of December 31, 2025, and the company expects this to fund operations into 2027.
Prime highlighted “breakthrough” Phase 1/2 data for PM359 in chronic granulomatous disease and is working toward final FDA alignment to submit a biologics license application. It plans to file IND and/or CTA applications for its Wilson Disease program PM577 in the first half of 2026 and for its Alpha-1 Antitrypsin Deficiency program PM647 in mid-2026, with initial clinical data for both targeted in 2027. The company is also advancing a cystic fibrosis program supported by the Cystic Fibrosis Foundation and continues its ex vivo CAR-T collaboration with Bristol Myers Squibb, positioning its Prime Editing platform for broader clinical validation.
Prime Medicine, Inc. furnished an updated corporate presentation on its investor website, with the materials attached as Exhibit 99.1. The presentation, dated January 2026, is provided under a Regulation FD disclosure to share information with the market in a broadly accessible way. The company states that this information is being furnished rather than filed, which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
Prime Medicine, Inc. (PRME) furnished an 8‑K to announce it issued a press release covering financial results and business highlights for the quarter ended September 30, 2025.
The disclosure was made under Item 2.02 and includes Exhibit 99.1 (Press Release dated November 7, 2025). The information is furnished and shall not be deemed filed under Section 18 of the Exchange Act, nor incorporated by reference, except as expressly stated by specific reference.
Prime Medicine’s common stock trades on The Nasdaq Global Market under the symbol PRME.
Prime Medicine, Inc. furnished a corporate update through a new investor presentation posted on its website on September 8, 2025. The company made the presentation, dated September 2025, available as Exhibit 99.1 to this report under a Regulation FD disclosure item.
The material is being treated as furnished, not filed, which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.